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The geopolitical drivers that influence human migration are complex and subject to 7 
change often influenced by conflict. Within this editorial, the term migrant is used as 8 
a generic for the heterogeneous population of asylum seekers, economic migrants 9 
and refugees. Population flows into Europe have reached unprecedented levels 10 
during the last few years. It is believed that some 355,361 new arrivals reached 11 
Europe by sea during 2016 (figure 1; data2.unhcr.org/en/situations/mediterranean), 12 
and predicted to reach 400 million by 2050. These are largely comprised of asylum 13 
seekers from Syria, Afghanistan Iraq and Nigeria. Beside political and economic 14 
impacts, health issues are a concern amongst newly arrived individuals. These 15 
countries have higher infection rates for diseases such as tuberculosis, with 16 
Afghanistan, Nigeria and Somalia having incidence rates of 125-332/100,000 of the 17 
population. Migrant and refugee populations are particularly vulnerable as often they 18 
have endured challenging journeys to Europe in less than desirable living conditions. 19 
Indeed, these stressful circumstances can result in activation of previously latent 20 
infection. Given these figures, it is not surprising that tuberculosis should be 21 
considered among newly arrived asylum seekers. Within the European economic 22 
area, some 25% of all cases of tuberculosis occur in foreign-born individuals [1]. 23 
Over 86% of European countries have implemented a tuberculosis screening 24 
programme for newly arrived asylum seekers. 25 
 26 
Other health priority areas encompass communicable respiratory and 27 
gastrointestinal infections, psychological trauma, drug abuse and pregnancy. Despite 28 
the conditions that many migrants have endured during their journey to Europe, the 29 
majority are generally in good health. Specific screening generally includes infectious 30 
diseases such as tuberculosis, hepatitis B and C and HIV infection. More exotic 31 
infections have been described such as a cluster of cutaneous diphtheria amongst 32 
refugees arriving in Germany and Switzerland {Meinel,  #23135}, but occur relatively 33 
infrequently. Interestingly, several of these have been amongst those whose 34 
migratory routes took them through Libya. Indeed, cases of Plasmodium falciparum 35 
malaria have been reported amongst migrants who stayed in this presumed non-36 
endemic county [2]. Similarly, patients presenting with louse-borne relapsing fever 37 
have been described in migrants transitioning through Libya, far beyond the lifespan 38 
of the disease vector, clothing lice [3]. Both scenarios raise interesting and as yet 39 
unresolved transmission possibilities, serving to remind those working with migrant 40 
healthcare of the need for continued vigilance. Often newly arrived migrants are 41 
detained in overcrowded conditions that can facilitate the transmission of infectious 42 
diseases as seen with a recent outbreak of measles [4]. Many have poorly 43 
documented vaccination histories, thus deployment of vaccines is a priority amongst 44 
such groups [5]. Within this issue, the review by Castelli and Sulis (this issue) and 45 
provides an overview of the phases of migration from first arrival to stable 46 
resettlement and evaluates the infection risks associated with the intervening 47 
transitional stages [5]. 48 
 49 
Given the huge influx of migrants from the south and east, migratory pathways from 50 
Latin America are often overshadowed. Within this group, presence of Chagas 51 
disease caused by Trypanosoma cruzi, is a particularly concerning. In many, this will 52 
be asymptomatic upon entry, but with potential to evolve to its chronic disease 53 
consequences of cardiomyopathy, gastrointestinal involvement with potentially fatal 54 
outcome. Monge-Maillo and Lopez-Velez (this issue), report that some 68,000 to 55 
120,000 individuals with Chagas disease currently reside within Europe with the 56 
majority undiagnosed [6] . Cost benefit analysis clearly demonstrated the economic 57 
benefits associated with screening migrants from Latin America, particularly from 58 
regions such as Bolivia and Paraguay [6, 7]. The remaining dilemma is whether such 59 
a screening programme should apply to all migrants from Latin America, or be 60 
targeted to particular high risk groups? The trade off in cost would need to be offset 61 
against increased complexity for healthcare providers when deciding whether to 62 
implement screening. 63 
 64 
In conclusion, vaccination to prevent spread of communicable disease and screening 65 
for sexually transmitted infections and diseases such as tuberculosis, viral hepatitis 66 
and HIV, coupled with targeted screening based on country of origin are justifiable 67 
and economically prudent. Beyond such measures, fear of introduction of exotic 68 
infectious diseases appears to be unsubstantiated amongst migrant populations 69 
beyond those risks shared by the whole population within our increasingly globalized 70 
world.  71 
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Figure 1: Migratory pathways and countries of origin (data correct as of 11.4.17 101 
data2.unhcr/org/en/situations/mediterranean). 102 
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